SCHEMBL358873

SCHEMBL358873

CC(=O)CC1COCCC1=O

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 3/20 0.33
MT-CO2 P00403 1/20 0.33
ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7538188 0.83 ITGB3 (0.34) MT-CO2ALOX5
SCHEMBL6023505 0.78 CYP2D6 (0.37)
SCHEMBL3327529 0.76
SCHEMBL14101011 0.73 NOS2 (0.30)
SCHEMBL14169479 0.73 NOS1 (0.38)
SCHEMBL14635516 0.72
SCHEMBL4869060 0.72 METAP1 (0.34)
SCHEMBL3325656 0.72 PDK1 (0.32)
SCHEMBL16503645 0.71 TLR4 (0.36) TLR4MT-CO2ALOX5
SCHEMBL1397437 0.71 NPC1 (0.45) TLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674115-B2 CRTH2 modulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-03-18 US disclosed
US-8674115-B2 CRTH2 modulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-03-18 US disclosed
US-8674115-B2 CRTH2 modulators IRONWOOD PHARMACEUTICALS, INC. (US) 2014-03-18 US disclosed
US-20130259830-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-10-03 US disclosed
US-20130259830-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-10-03 US disclosed
US-20130259830-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2013-10-03 US disclosed
EP-2516416-A1 CRTH2 MODULATORS Ironwood Pharmaceuticals, Inc. (US) 2012-10-31 EP disclosed
WO-2012009134-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-01-19 WO disclosed
WO-2012009134-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-01-19 WO disclosed
WO-2011079007-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 WO disclosed
WO-2011079007-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 WO disclosed
US-20110150834-A1 CRTH2 MODULATORS WELLS FARGO BANK, NATIONAL ASSOCIATION 2011-06-23 US disclosed
US-20110150834-A1 CRTH2 MODULATORS WELLS FARGO BANK, NATIONAL ASSOCIATION 2011-06-23 US disclosed
US-20110150834-A1 CRTH2 MODULATORS WELLS FARGO BANK, NATIONAL ASSOCIATION 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150834-A1 CRTH2 MODULATORS HRH2, HRH1, NR1H2 TLR4 2387/4885MT-CO2 981/4885ALOX5 515/4885
US-20130259830-A1 CRTH2 MODULATORS HRH2, HRH1, NR1H2 TLR4 2387/4885MT-CO2 981/4885ALOX5 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.